Clinical pharmacology of opioids for pain

Clinical Journal of Pain

Volumn 18, Issue 4 SUPPL., 2002, Pages

  Inturrisi, Charles E ^a   Jamison, Robert N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Analgesic; Endogenous opioid; Euphoria; Morphinelike agonist; Opioid receptor; Opioid rotation

Indexed keywords

AMITRIPTYLINE; BUPRENORPHINE; BUTORPHANOL TARTRATE; CAFFEINE; CARBAMAZEPINE; CODEINE; DESIPRAMINE; DEXAMPHETAMINE; DIHYDROMORPHINE; FENTANYL; GABAPENTIN; HYDROMORPHONE; HYDROXYZINE; IMIPRAMINE; KAPPA OPIATE RECEPTOR; LEVOMEPROMAZINE; LEVORPHANOL; METHADONE; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NALBUPHINE; NOMORPHAN; NORTRIPTYLINE; NUBAIN N; OPIATE; ORAMORPH SR; OXY IR; OXYCODONE; OXYMORPHONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; PHENYTOIN; SIGMA OPIATE RECEPTOR; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR;

ARTICLE; BRAIN CORTEX; BRAIN STEM; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HUMAN; HYPERPOLARIZATION; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; OPIATE ADDICTION; PAIN; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; SPINAL CORD DORSAL HORN; THALAMUS; CHRONIC DISEASE; CLASSIFICATION; COMORBIDITY; DRUG TOLERANCE; MORTALITY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; REVIEW; RISK ASSESSMENT; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; CHRONIC DISEASE; COMORBIDITY; DRUG TOLERANCE; HUMAN; OPIOID-RELATED DISORDERS; PAIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECEPTORS, OPIOID; RISK ASSESSMENT; SUBSTANCE WITHDRAWAL SYNDROME; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS;

EID: 0036323891     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002508-200207001-00002     Document Type: Article

References (43)

1. Opioid analgesics
2. Opioid analgesic therapy
3. Problems of overarching importance, which transcend organ systems
4. Adjuvant analgesic agents
5. Molecular neurobiology of addiction
6. Opioids: First lessons from knockout mice
7. Spinal mechanisms and their modulation
8. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function
9. Novel receptor mechanisms for heroin and morphine-6-glucuronide analgesia
10. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: Plasma profiles, steady-state concentrations and the consequences of renal failure
11. Morphine-6-glucuronide concentrations and opioid-related side effects: A survey in cancer patients
12. The role of morphine glucuronides in cancer pain
13. Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites
14. Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio?
15. Methadone in cancer pain management: Individualize dose and titrate to effect
16. New perspectives in our use of opioids
17. Old dogs, new tricks
18. d-methadone blocks morphine tolerance and N-methyl-D-aspartate (NMDA)-induced hyperalgesia
19. Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence
20. Update on the neurophysiology of pain transmission and modulation: Focus on the NMDA-receptor
21. NMDA-receptor antagonists in neuropathic pain: Experimental methods to clinical trials
22. MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain
23. Abuse potential of morphine/dextromethorphan combinations
24. MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients
25. Kappa-opioids produce significantly greater analgesia in women than in men
26. Gender difference in analgesic response to the kappa-opioid pentazocine
27. Naloxone reversal of buprenorphine-induced respiratory depression
28. Opioid rotation for toxicity reduction in terminal cancer patients
29. Accuracy in equianalgesic dosing: Conversion dilemmas
30. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence
31. Neuropsychiatric toxicity of opioids
32. Does prolonged oral treatment with sustained-release morphine tablets influence immune function?
33. Pain control by immune-derived opioids
34. Opioids and pain management
35. Patterns of narcotic drug use in a cancer pain clinic
36. Drug addiction and drug abuse
37. Addiction rare in patients treated with narcotics
38. Management of pain during debridement: A survey of U.S. burn units
39. Trends in medical use and abuse of opioid analgesics
40. Responding rationally to recent reports of abuse/diversion of Oxycontin